11 research outputs found
First application of hemi-body electron beam irradiation for Kaposi sarcoma at the lower extremities
Kaposi’s sarcoma (KS) is a systemic neoplastic disease that can present cutaneous symptoms and is usually treated with a systematic approach due to its extent. Due to its radiosensitivity, radiotherapy is considered one of its main treatments, for palliation and local control of the skin and mucosal lesions. The aim of this paper was to report the first case of KS treated by hemi-body electron irradiation protocol in Greece. A fractionated 40 Gy hemi-body electron irradiation was prescribed to a 60-year-old male patient with KS at his legs. Dose uniformity was verified on a daily basis by thermo luminescence dosimetry (TLD). The treatment resulted to complete clinical response. Limited irradiation-derived side effects appeared. This is the first case ever to be treated with hemi-body electron irradiation protocol in Greece. To the best of our knowledge, this is also the first time that a single field hemi-body electron beam irradiation at a total skin electron beam (TSEB)-like configuration is reported to be used for KS
A novel Hemi-Body Irradiation technique using electron beams (HBIe−)
Purpose Certain radiation responsive skin diseases may develop symptoms on the upper or the lower half of the body. The concept of a novel Hemi-Body Electron Irradiation (HBIe−) technique, described in this work, provides a low cost, LINAC based, intermediate treatment option in between extremely localized and Total Skin irradiation techniques. Materials and methods The HBIe− technique, developed in our department, incorporates a custom crafted treatment chamber equipped with adjustable Pb shielding and a single electron beam in extended Source-Skin Distance (SSD) setup. The patient is positioned in 'Stanford' technique positions. The geometrical setup provides both optimal dose homogeneity and dose deposition up to a depth of 2 cm. To confirm this, the following characteristics were measured and evaluated: a) percentage depth dose (PDD) on the treatment plane produced by a single electron beam at perpendicular incidence for six fields at 'Stanford' angles, b) 2D profile of the entrance dose on the treatment plane produced by a single field and c) the total surface dose on an anthropomorphic phantom delivered by all 6 fields. Results The resulting homogeneity of the surface dose in the treatment plane for an average patient was 5–6%, while surface dose homogeneity on the anthropomorphic phantom was 7% for both the upper and the lower HBIe− variants. The total PDD exhibits an almost linear decrease to a practical range of 2 g/cm2. Conclusion In conclusion, HBIe− was proven effective in delivering the prescribed dose to the target area, while protecting the healthy skin
First treatment of mycosis fungoides by total skin electron beam (TSEB) therapy in Greece
BackgroundMycosis fungoides (MF), the most common subtype of cutaneous T-Cell Lymphoma (CTCL), is a rare chronic skin neoplasia. Total skin electron irradiation has been employed along with a variety of other topical or systemic treatments for MF management.AimTo report the first case treated by TSEB irradiation protocol in Greece.Materials and methodsA fractionated 36[[ce:hsp sp="0.25"/]]Gy total skin electron beam (TSEB) therapy was prescribed to a 65-years-old male patient with mycosis fungoides (MF), stage IIB, refractory to several treatments during a 20-year period. Dose uniform delivery was monitored by thermo-luminescence dosimetry.Results and discussionThe homogeneous skin dose distribution resulted in a complete clinical response. Limited, irradiation-oriented, side effects appeared.ConclusionsThe first TSEB irradiation prescription in Greek medical chronicles was proved effective in this case of tumor stage MF (T3-IIB), which had been refractory to several single or combination treatments
A novel Hemi-Body Irradiation technique using electron beams (HBIe(-))
Purpose: Certain radiation responsive skin diseases may develop symptoms
on the upper or the lower half of the body. The concept of a novel
Hemi-Body Electron Irradiation (HBIe(-)) technique, described in this
work, provides a low cost, LINAC based, intermediate treatment option in
between extremely localized and Total Skin irradiation techniques.
Materials and methods: The HBIe(-) technique, developed in our
department, incorporates a custom crafted treatment chamber equipped
with adjustable Pb shielding and a single electron beam in extended
Source-Skin Distance (SSD) setup. The patient is positioned in
‘Stanford’ technique positions. The geometrical setup provides both
optimal dose homogeneity and dose deposition up to a depth of 2 cm. To
confirm this, the following characteristics were measured and evaluated:
a) percentage depth dose (PDD) on the treatment plane produced by a
single electron beam at perpendicular incidence for six fields at
‘Stanford’ angles, b) 2D profile of the entrance dose on the treatment
plane produced by a single field and c) the total surface dose on an
anthropomorphic phantom delivered by all 6 fields.
Results: The resulting homogeneity of the surface dose in the treatment
plane for an average patient was 5-6%, while surface dose homogeneity
on the anthropomorphic phantom was 7% for both the upper and the lower
HBIe(-) variants. The total PDD exhibits an almost linear decrease to a
practical range of 2 g/cm(2).
Conclusion: In conclusion, HBIe(-) was proven effective in delivering
the prescribed dose to the target area, while protecting the healthy
skin
Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
Background & purpose: Although rare, cutaneous lymphomas represent a separate entity in hematologic oncology. T cell origin lymphomas are most common, with Mycosis Fungoides (MF) accounting for about 50–70% of cases. Sezary Syndrome (SS), which represents the leukemic varian of MF, accounts for 3% of Cutaneous T Cell Lymphomas (CTCL). Total Skin Electron Beam Therapy (TSEB) is included at the mainstream of treatment choices for CTCL. The scope of this study is to evaluate the effectiveness and toxicity of two treatment schedules of TSEB. Methods and materials: We report our experience with TSEB in the management of MF and SS, as of 14 patients treated in our institution from 2011 to 2015. 8 patients received the 12 Gy (low dose) scheme while 6 patients were managed with 36 Gy (standard or full dose scheme) according to six dual field Stanford technique. The endpoints were overall response rate, duration of response and toxicity of treatment. Results: After a median follow up of 2.5 years we noted excellent treatment outcome, with both schemes being well tolerated and resulting in comparable response rates. The overall response rate for both treatment regimens was over 87.5%. Treatment was well tolerated with mild toxicity. Conclusion: The role of TSEB in the management of MF and SS is well established. The low dose TSEB schedule of 12 Gy is an effective treatment option, since therapeutic results are more than acceptable, compliance is excellent and toxicity is minimal. Moreover, the evidence that it can be repeated safely makes it more attractive than the standard 36 Gy scheme, when a patient is referred to radiation treatment according to treatment guidelines
Transformation of Physical DVHs to Radiobiologically Equivalent Ones in Hypofractionated Radiotherapy Analyzing Dosimetric and Clinical Parameters: A Practical Approach for Routine Clinical Practice in Radiation Oncology
Purpose. The purpose of this study was to transform DVHs from physical to radiobiological ones as well as to evaluate their reliability by correlations of dosimetric and clinical parameters for 50 patients with prostate cancer and 50 patients with breast cancer, who were submitted to Hypofractionated Radiotherapy. Methods and Materials. To achieve this transformation, we used both the linear-quadratic model (LQ model) and the Niemierko model. The outcome of radiobiological DVHs was correlated with acute toxicity score according to EORTC/RTOG criteria. Results. Concerning the prostate radiotherapy, there was a significant correlation between RTOG acute rectal toxicity and () and () dosimetric parameters, calculated for Gy. Moreover, concerning the breast radiotherapy there was a significant correlation between RTOG skin toxicity and dosimetric parameter, calculated for both Gy () and Gy (). The new tool seems reliable and user-friendly. Conclusions. Our proposed model seems user-friendly. Its reliability in terms of agreement with the presented acute radiation induced toxicity was satisfactory. However, more patients are needed to extract safe conclusions
A Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer
A Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer
Introduction: The aim of this analysis was a retrospective evaluation of
the efficacy and toxicity of 2 hypofractionated irradiation schedules
compared to conventional therapy in post-mastectomy patients. Methods: 3
irradiation schedules were analyzed: 48.30 Gy in 21 fractions (group A,
n = 60), 42.56 Gy in 16 fractions (group B, n = 27) and 50 Gy in 25
fractions (group C, n = 30) of the front chest wall. All groups were
also treated with a supraclavicular field, with 39.10 Gy in 17 fractions
(group A), 37.24 Gy in 14 fractions (group B) or 45 Gy in 25 fractions
(group C). Results: No local recurrences were noted in any group during
36 months of follow-up. Acute skin toxicity presented in all groups,
with 58.3%, 70.4% and 60% of grade I; 35%, 25.9% and 40% of grade
II; 6.7%, 3.7% and 0% of grade III being seen in groups A, B and C,
respectively. Late skin toxicity was noted only as grade I in 16.7%,
25.9% and 26.7% of groups A, B and C, respectively. No significant
difference was noted among all groups for either acute or late skin
toxicity, or for radio-pneumonitis (chi(2) test, p > 0.05). Conclusion:
All schedules were equally effective with equivalent toxicity. A
prospective randomized study is needed to confirm our results. (C) 2016
S. Karger GmbH, Freibur
Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer
AIM: To evaluate the effect of chemotherapy to the acute toxicity of a
hypofractionated radiotherapy (HFRT) schedule for breast cancer.
METHODS: We retrospectively analyzed 116 breast cancer patients with T1,
2N0Mx. The patients received 3-D conformal radiotherapy with a total
physical dose of 50.54 Gy or 53.2 Gy in 19 or 20 fractions according to
stage, over 23-24 d. The last three to four fractions were delivered as
a sequential tumor boost. All patients were monitored for acute skin
toxicity according to the European Organization for Research and
Treatment of Cancer/Radiation Therapy Oncology Group criteria. The
maximum monitored value was taken as the final grading score.
Multivariate analysis was performed for the contribution of age,
chemotherapy and 19 vs 20 fractions to the radiation acute skin
toxicity.
RESULTS: The acute radiation induced skin toxicity was as following:
grade. 27.6%, grade. 7.8% and grade. 2.6%. No significant correlation
was noted between toxicity grading and chemotherapy (P = 0.154, chi(2)
test). The mean values of acute toxicity score in terms of chemotherapy
or not, were 0.64 and 0.46 respectively (P = 0.109, Mann Whitney test).
No significant correlation was also noted between acute skin toxicity
and radiotherapy fractions (P = 0.47, chi(2) test). According to
univariate analysis, only chemotherapy contributed significantly to the
development of acute skin toxicity but with a critical value of P =
0.05. However, in multivariate analysis, chemotherapy lost its
statistical significance. None of the patients during the 2-years of
follow-up presented any locoregional relapse.
CONCLUSION: There is no clear evidence that chemotherapy has an impact
to acute skin toxicity after an HFRT schedule. A randomized trial is
needed for definite conclusions. (c) 2014 Baishideng Publishing Group
Inc. All rights reserved